New Drug Combos Promising in Higher-Risk RhabdomyosarcomaNew Drug Combos Promising in Higher-Risk Rhabdomyosarcoma
Temsirolimus combined with chemotherapy increased event-free survival in rhabdomyosarcoma, but the addition of irinotecan did not improve outcomes, new research shows. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 5, 2014 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Scientists map gene changes driving tumors in common pediatric soft-tissue cancer
Scientists have mapped the genetic changes that drive tumors in rhabdomyosarcoma, a pediatric soft-tissue cancer, and found that the disease is characterized by two distinct genotypes. The genetic alterations identified in this malignancy could be useful in developing targeted diagnostic tools and treatments for children with the disease. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - January 23, 2014 Category: Science Source Type: news
NIH scientists map gene changes driving tumors in common pediatric soft-tissue cancer
(NIH/National Cancer Institute) Scientists have mapped the genetic changes that drive tumors in rhabdomyosarcoma, a pediatric soft-tissue cancer, and found that the disease is characterized by two distinct genotypes. The genetic alterations identified in this malignancy could be useful in developing targeted diagnostic tools and treatments for children with the disease. The study, by researchers at the National Cancer Institute, part of the National Institutes of Health, and their colleagues, appeared in the Jan. 23, 2014, issue of the journal Cancer Discovery. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - January 23, 2014 Category: Biology Source Type: news
JCI early table of contents for Dec. 16, 2013
(Journal of Clinical Investigation) This release contains summaries, links to PDFs, and contact information for the following newsworthy papers to be published online Dec. 16, 2013 in the JCI: "A mouse model to evaluate potential age-promoting compounds," "Hybrid protein deregulates complement in dense deposit disease," "Therapeutic antagonists of microRNAs deplete leukemia-initiating cell activity," "Alveolar rhabdomyosarcoma-associated PAX3-FOXO1 promotes tumorigenesis via Hippo pathway suppression," "Nervous glucose sensing regulates postnatal beta cell proliferation and glucose homeostasis," and more. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 16, 2013 Category: Cancer & Oncology Source Type: news
Drugs identified that enhance oxidative stress as possible weapon against most common pediatric soft tissue tumor
Drugs that enhance a process called oxidative stress were found to kill rhabdomyosarcoma tumor cells growing in the laboratory and possibly bolstered the effectiveness of chemotherapy against this aggressive tumor of muscle and other soft tissue. The findings are the latest from the St. Jude Children's Research Hospital-Washington University Pediatric Cancer Genome Project and appear in the December 9 edition of the scientific journal Cancer Cell.Oxidative stress is caused when oxygen-free radicals and other byproducts of cell metabolism build up in cells. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - December 12, 2013 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news
Gene sequencing project finds family of drugs with promise for treating childhood tumor
(St. Jude Children's Research Hospital) Drugs that enhance a process called oxidative stress were found to kill rhabdomyosarcoma tumor cells growing in the laboratory and possibly bolstered the effectiveness of chemotherapy against this aggressive tumor of muscle and other soft tissue. The findings are the latest from the St. Jude Children's Research Hospital-Washington University Pediatric Cancer Genome Project and appear in the Dec. 9 edition of the scientific journal Cancer Cell. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 9, 2013 Category: Global & Universal Source Type: news
Combination therapy could treat common children's cancer
A dual-pronged strategy using two experimental cancer drugs together could successfully treat a childhood cancer by inhibiting tumour growth and blocking off the escape routes it uses to become resistant to treatment, finds a new study. Scientists at The Institute of Cancer Research, London, found that combining two separate molecularly targeted therapies could stop processes driving growth in a cancer called rhabdomyosarcoma, a major cause of cancer death in children... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - November 5, 2013 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news
Dense Embryonal or Alveolar Rhabdomyosarcoma?Dense Embryonal or Alveolar Rhabdomyosarcoma?
The authors elucidate the differentiation of alveolar and embryonal rhabdomyosarcoma variants utilizing both histology and evaluation of fusion status. American Journal of Clinical Pathology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 23, 2013 Category: Consumer Health News Tags: Pathology & Lab Medicine Journal Article Source Type: news
Slide Show: Nasal Tumors
This nasal tumor slide show features pathology images of nasal neuroblastoma, rhabdomyosarcoma, melanoma, hemangiopericytoma, and lymphoma at various magnifications. (Source: Cancer Network)
Source: Cancer Network - September 12, 2013 Category: Cancer & Oncology Source Type: news
EMA opens public consultation on standard paediatric investigation plans for two types of cancer in children
Source: EMA
Area: News
The European Medicines Agency has opened a public consultation on two standard paediatric investigation plans (PIPs) for two specific types of cancer with unmet medical needs in children, acute myeloid leukaemia and rhabdomyosarcoma.
A PIP sets out a programme for the development of a medicine to ultimately authorise its use in children. The goal of these standard PIPs is to support pharmaceutical companies to propose a plan that is scientifically adapted to the medicine.
Compared to the progress made in other acute leukaemias, the outlook for children with myeloid leukaemia i...
Source: NeLM - News - February 22, 2013 Category: Drugs & Pharmacology Source Type: news
